CarVin versus CarEto - A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors

Submission date	Recruitment status	Prospectively registered
12/09/2003	Stopped	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
12/09/2003	Stopped	Results
Last Edited	Condition category	Individual participant data
04/07/2011	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ernie Marshall

Contact details

Clatterbridge Centre for Oncology Clatterbridge Road Bebington Wirral United Kingdom CH63 4JY +44 0151 334 1155 ernie.marshall@ccotrust.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0067120650

Study information

Scientific Title

Study objectives

A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cancer: Small cell lung cancer

Interventions

- 1. Chemotherapy with carboplatin and vinorelbine
- 2. Chemotherapy with carboplatin and etoposide

Added July 2008: trial stopped because of poor recruitment

Intervention Type

Other

Phase

Phase II

Primary outcome measure

- 1. Toxicity
- 2. Tumour response

Secondary outcome measures

Not provided at time of registration

Overall study start date

08/04/2002

Completion date

08/04/2006

Reason abandoned (if study stopped)

Insufficient personel

Eligibility

Key inclusion criteria

- 1. Elderly patients >65 years with good prognosis and Eastern Cooperative Oncology Group (ECOG) p/s <2
- 2. Confirmed small cell lung cancer not considered eligible for aggressive multimodality therapy

Participant type(s)

Patient

Age group

Senior

Sex

Not Specified

Target number of participants

Total target recruitment = 80 patients

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

08/04/2002

Date of final enrolment

08/04/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Clatterbridge Centre for Oncology Wirral United Kingdom CH63 4JY

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.doh.gov.uk

Funder(s)

Funder type

Government

Funder Name

Clatterbridge Centre for Oncology NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration